CSAAI 2018 A Midsummer Night's Wheeze
This program is designed to teach the busy allergist new medications and techniques for treating allergic diseases. Increasingly, the clinical allergist sees more people with a number of evolving problems including food allergies and sensitivity as well as asthma, mast cell diseases, sinusitis, non-allergic rhinitis and different types and degrees of anaphylaxis. With food allergies, the allergist needs to know the latest advances in oral desensitization including pretreatment with medications as well as diagnosis, management and prevention. Increasingly, asthmatics are being treated by the allergist, not the pulmonologist and they have a new armamentarium of biologics available to use. This program will familiarize allergists with the various new medications and give them the skills needed to optimally individualize treatment based upon the patient’s disease state, medical history and laboratory values including eosinophil counts. The allergist also needs to also know advances in treatment of anaphylaxis in infants and children as well as adults. This program will bring the participant up-to-date on the latest information on treating and preventing allergic illnesses, treating anaphylaxis, sinus disease, non-allergic rhinitis, mastocytosis and mast cell activation syndrome. The program will also discuss asthma prevention via environmental controls as well as asthma medication and treatment strategies.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the California Society of Allergy, Asthma and Immunology (CSAAI) . The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 12 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported in part by an independent medical education grant from Optinose.
Practicing allergists, primary care physicians, and allied health care professionals in the field of allergy and immunology.
Upon completion of this activity, participants should be able to:
- Summarize recent advances in understanding and treatment of mastocytosis and mast cell activation syndrome
- Review the allergenic aspects of the dust mite
- Recognize the safety issues and efficacy of various asthma treatments in adults
- Describe the treatment of anaphylaxis in infants and toddlers
- Explain the use of SLIT in the treatment of allergic rhinitis and asthma
- Summarize the treatment choices in severe chronic rhinosinusitis
- Outline the treatment of anaphylaxis when the allergen is a glycolipid
- Review the protocol for food allergy desensitization
- Outline the prevention, diagnosis and therapy of food allergies
- 12.00 AMA PRA Category 1 Credit™
- 12.00 Attendance